Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerebral endothelial cell-derived exosomes are small extracellular vesicles (exosomes) secreted by cerebral endothelial cells. These nanovesicles (typically 40–150 nm in diameter) mediate intercellular communication within the brain by transferring proteins, lipids, and genetic material—especially microRNAs—to recipient cells such as neurons and neural stem cells. Exosomes from both nonischemic (nCEC-exos) and ischemic (isCEC-exos) cerebral endothelial cells have been shown to promote axonal growth in neurons; isCEC-exos exhibit a more robust effect on axonal remodeling after stroke or ischemic injury. The mechanism involves modulation of miRNA profiles in recipient neurons leading to downregulation of inhibitory proteins for axonal outgrowth. In animal models, these exosomes also support neurogenesis and cognitive function recovery following neurological injury or disease such as stroke or diabetes-induced cognitive impairment[1][2][5]. They are being investigated primarily as experimental biologics for neurorestorative therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cerebral endothelial cell-derived exosomes.